Coegin PharmaNGM:COEGIN +3.72%29 EBITDA Margin % is -1,378.77% as of Mar. 2026. GuruFocus rates NGM:COEGIN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 943 Biotechnology companies, Coegin Pharma ranks worse than 89.61% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Coegin Pharma's EBITDA for the
three
months ended in Mar. 2026 was kr-4.03 Mil. Coegin Pharma's Revenue for the
three
months ended in Mar. 2026 was kr0.29 Mil. Therefore, Coegin Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was -1,378.77%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Coegin Pharma EBITDA Margin % Related Terms
Coegin Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Coegin Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:COEGIN vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Coegin Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coegin Pharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coegin Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Coegin Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coegin Pharma (NGM:COEGIN) has a EBITDA Margin % of -1,378.77% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Coegin Pharma and its competitors. According to the industry distribution chart, Coegin Pharma ranks #845 out of 943 companies in the Biotechnology industry, placing it in the top 89.6%.
Is Coegin Pharma's EBITDA Margin % too high?
Coegin Pharma's current EBITDA Margin % is -1,378.77%. Based on the distribution chart, Coegin Pharma ranks #845 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coegin Pharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Coegin Pharma ranks #845 out of 943 companies for EBITDA Margin %. This places Coegin Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Coegin Pharma and its competitors. Coegin Pharma's current EBITDA Margin % is -1,378.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current EBITDA Margin % of -1,378.77%. The current EBITDA Margin % is -1,378.77%. Coegin Pharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current EBITDA Margin % is -1,378.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
29GF Score
Get the complete analysis for NGM:COEGIN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:COEGIN has been successfully added to your 
